Skip to content
RDL Network logo
GLP1 receptor agonist with add-on SGLT2 inhibitor therapy is associated with lower risks of major adverse cardiovascular events: a population-based and machine learning causal inference analysis — Zhiyao Luo (2025) | RDL Network